4.6 Article

C-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal Vaccine

Journal

PLOS ONE
Volume 10, Issue 5, Pages -

Publisher

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0126352

Keywords

-

Funding

  1. Ministry of Health and Welfare of Japan
  2. Ministry of Education, Culture, Sports, Science, and Technology of Japan
  3. Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries, and Food Industry
  4. Program for Promotion of Basic and Applied Research for Innovations in Bio-oriented Industry
  5. Japan Science and Technology Agency, Core Research for Evolutional Science and Technology (CREST)
  6. Kowa Life Science Foundation
  7. Mochida Memorial Foundation for Medical and Pharmaceutical Research
  8. Grants-in-Aid for Scientific Research [26293111, 26860078, 15K18950] Funding Source: KAKEN

Ask authors/readers for more resources

Efficient vaccine delivery to mucosal tissues including mucosa-associated lymphoid tissues is essential for the development of mucosal vaccine. We previously reported that claudin-4 was highly expressed on the epithelium of nasopharynx-associated lymphoid tissue (NALT) and thus claudin-4-targeting using C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE) effectively delivered fused antigen to NALT and consequently induced antigen-specific immune responses. In this study, we applied the C-CPE-based vaccine delivery system to develop a nasal pneumococcal vaccine. We fused C-CPE with pneumococcal surface protein A (PspA), an important antigen for the induction of protective immunity against Streptococcus pneumoniae infection, (PspA-C-CPE). PspA-C-CPE binds to claudin-4 and thus efficiently attaches to NALT epithelium, including antigen-sampling M cells. Nasal immunization with PspA-C-CPE induced PspA-specific IgG in the serum and bronchoalveolar lavage fluid (BALF) as well as IgA in the nasal wash and BALF. These immune responses were sufficient to protect against pneumococcal infection. These results suggest that C-CPE is an efficient vaccine delivery system for the development of nasal vaccines against pneumococcal infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available